In the world of thoracic oncology, we often talk about “breakthroughs”, the moments where data becomes a discovery, and discovery becomes a life-extending treatment. But today, the greatest barrier to these breakthroughs isn’t a lack of scientific clinical innovation; it is a policy-driven bottleneck.

The 2025 financial year has been a period of significant growth, strategic evolution, and clinical impact for the TOGA. As we release our 2025 Annual Report, we reflect on the past five years defined by o...

Since TOGA’s inception, we have welcomed research proposals in the areas of prevention and quality of care. However, until now, there has not been a dedicated representative group within TOGA to specifically review and support work in this space. The establishment of ...

As the thoracic oncology landscape continues to evolve, so too must the structures that support research development, collaboration and trial delivery. In 2026, TOGA has refined its Working Group structure to better reflect where research is heading across prevention, early detection, disease-specific innovation, supportive care, and translational...

Designing and budgeting a clinical trial can feel daunting once your research concept has been endorsed, especially when facing regulatory, budgeting and operational questions for the first time.

This guide walks you through the essential steps to create a budget and conduct a clinical trial in Australia, from ...